Vertex (NASDAQ: VRTX) director granted 107 deferred stock units as equity pay

Rhea-AI Filing Summary

SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Bruce I. Sachs received a routine equity grant in the form of deferred stock units. He was awarded 107.345 deferred stock units at a reference price of $442.50 per unit, each representing one share of common stock. After this grant, Sachs holds 15,671.866 deferred stock units. According to the terms, these units are paid out in common stock upon the earliest of his board service ending, a change of control of the company, or his disability or death.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SACHS BRUCE I

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	107.345	$442.50	$48K

Holdings After Transaction: Deferred Stock Units — 15,671.866 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Deferred stock units granted: 107.345 units Grant reference price: $442.50 per unit Total deferred units after grant: 15,671.866 units +2 more

5 metrics

Deferred stock units granted 107.345 units Grant of deferred stock units on April 15, 2026

Grant reference price $442.50 per unit Reference price used for the deferred stock unit award

Total deferred units after grant 15,671.866 units Director holdings in deferred stock units following the transaction

Underlying common stock 107.345 shares Common shares represented by the new deferred stock units

Conversion price $0.00 Deferred stock units have no separate exercise price

Key Terms

Deferred Stock Units, change of control, board of directors, Grant, award, or other acquisition

4 terms

Deferred Stock Units financial

"Each deferred stock unit represents one share of common stock"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

change of control financial

"upon the earliest to occur of (i) termination ... (ii) a change of control of our company"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

board of directors financial

"termination of Mr. Sachs' service on our board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SACHS BRUCE I

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	04/15/2026		A		107.345		(1)	(1)	Common Stock	107.345	$442.5	15,671.866	D

Explanation of Responses:

1. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did VRTX director Bruce Sachs report on this Form 4?

Bruce I. Sachs reported receiving a grant of 107.345 deferred stock units tied to Vertex common stock. This is a compensation-related equity award, not an open-market purchase or sale, and reflects part of his ongoing director compensation at Vertex Pharmaceuticals.

How many Vertex deferred stock units does Bruce Sachs hold after this transaction?

Following the April 15 grant, Bruce Sachs holds a total of 15,671.866 deferred stock units. Each unit corresponds to one share of Vertex common stock, giving a clear view of his accumulated director equity awards linked to VRTX stock performance over time.

At what price were Bruce Sachs’s new Vertex deferred stock units valued?

The 107.345 deferred stock units granted to Bruce Sachs were valued at $442.50 per unit. This figure represents the reference price used for the award calculation and helps indicate the notional value of this portion of his director equity compensation at grant.

What does each deferred stock unit for VRTX represent for Bruce Sachs?

Each deferred stock unit represents one share of Vertex common stock for Bruce Sachs. Instead of immediate stock delivery, these units accumulate and are later settled in actual common shares, aligning director compensation with long-term changes in Vertex’s share price performance.

When will Bruce Sachs receive Vertex common stock from these deferred stock units?

The deferred stock units are paid out in Vertex common stock upon the earliest of three events: Bruce Sachs leaving the board, a change of control of the company, or his disability or death. These conditions define when the deferred compensation becomes actual share ownership.

Is Bruce Sachs’s Form 4 for VRTX a buy or a routine award?

The Form 4 reflects a routine award, not an open-market stock purchase. Bruce Sachs acquired 107.345 deferred stock units as a grant, categorized as a “Grant, award, or other acquisition,” consistent with compensation practices rather than discretionary trading in Vertex shares.